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Abstract 
Objective: To investigate differences in clinical, psychological and psychophysical 
outcomes according to use of prophylactic medication (amitriptyline) in tension type 
headache (TTH). Methods: One hundred and seventy-three (n=173) individuals with 
TTH participated. Headache features and symptomatic medication intake were collected 
with a 4-weeks headache diary at baseline and at 6-months. Burden of headache 
(Headache Disability Inventory-HDI), sleep quality (Pittsburgh Sleep Quality Index-
PSQI), anxiety/depression (Hospital Anxiety and Depression Scale-HADS), and 
trait/state anxiety levels (State-Trait Anxiety Inventory-STAI) were also assessed at 
baseline. Pressure pain thresholds (PPT) were assessed over the temporalis, C5-C6 
joint, second metacarpal, and tibialis anterior at baseline. Differences between subjects 
taking or not taking prophylactic medication based on self-perceived effectiveness of 
the medication on headache characteristics were assessed. Results: Forty-nine (28%) 
reported taking prophylactic medication for the headaches (amitriptyline: 100%). From 
these, eleven (23%) reported no effect, 25 (51%) reported moderate effect and 13 (26%) 
reported positive effect with medication. Patients taking prophylactic medication had 
longer headache history, higher frequency of headaches (61% CTTH), higher headache 
burden, worse quality of sleep, and higher depression than those not taking medication. 
Prophylactic medication was less effective in patients with generalized pressure pain 
hyperalgesia. No other significant differences were found. Conclusions: Prophylactic 
medication is used by TTH patients with higher headache frequency, higher headache 
burden, worse sleep quality, and higher depression. Lower effectiveness of prophylactic 
amitriptyline was associated with widespread pain hyperalgesia. 
Keywords: tension type headache; medication intake; amitriptyline, pressure pain. 
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Introduction 
Tension type headache (TTH) is a pain disorder with a prevalence of 42% in the 
general population.
1 
In the last Global Burden of Disease Study, headache (mostly TTH 
and migraine) was found to be the second most prevalent chronic pain condition in the 
world.
2 
Tension type headache has an important socio-economic impact for the society 
with a reported cost of $21 billion annually, from which 92% were indirect costs.
3
 
        Pharmacological treatment of patients with TTH includes symptomatic (acute) and 
prophylactic medication. Symptomatic (acute) medication refers to treatment of a single 
headache and it is usually considered as over-the counted drug medication. Prophylactic 
medication refers to treatment used, and generally maintained for several weeks/months, 
for preventing headache attacks. The clinical practice guideline of European Federation 
of Neurological Societies recommends amitriptyline as the first-line prophylactic drug 
for patients with TTH exhibiting high frequency of headaches, i.e., chronic tension type 
headache (CTTH), but also in individuals with episodic tension type headache with high 
frequency of headaches, i.e., frequent episodic tension type headache (FETTH).
4 
In fact, 
this recommendation is supported by available data. For instance, a recent meta-analysis 
has found high-quality evidence suggesting that tricyclic antidepressants (amitriptyline 
dose 50 to 150 mg) are superior to placebo for reducing headache frequency and the 
number of analgesic tablets consumed in patients with CTTH;
5 
nevertheless, showing 
greater adverse effects.
6
 
         Although the mechanisms underlying TTH are not completely understood, current 
evidence supports that a hyper-excitability of the central nervous system may be one 
factor involved in the development of TTH.
7 
In fact, current theories include associated 
factors such as anxiety/depression,
8 
sleep disturbances,
9 
and emotional stress
10 
in this 
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process of central sensitization. No study has previously investigated if these variables 
are associated to prophylactic medication intake in subjects TTH with high frequency of 
headaches. Interestingly, practice guidelines suggest a patient-centered approach when 
deciding whether to start prophylactic medication;
11 
however, many patients who could 
benefit from prophylactic treatment are not receiving it.
12 
A recent systematic review 
found moderate-quality evidence indicating that depression, anxiety, poor sleep, stress, 
and poor self-efficacy for managing pain were potential prognostic factors for 
unfavorable outcomes from prophylactic treatment in chronic headaches.
13 
Therefore, 
better understanding of those variables associated to prophylactic medication intake 
could help to better identify critical areas for medication treatment of TTH. The aim of 
this longitudinal study was to investigate differences in clinical, psychological and pain 
sensitivity outcomes related to prophylactic medication intake in patients with TTH. We 
hypothesized that individuals with TTH: 1) taking prophylactic amitriptyline medication 
will exhibit better clinical, psychological and psychophysical outcomes at 6 months 
follow-up than those not taking prophylactic medication; and, 2) in whom prophylactic 
medication was more effective exhibit better clinical, psychological and psychophysical 
outcomes than those in whom prophylactic medication was not effective. 
Methods 
Participants 
Patients with a diagnosis of TTH were recruited from three different university-
based hospitals (University Rey Juan Carlos, Aalborg University, Urbino University) 
from September 2014 to January 2017. Participants were diagnosed following the last 
criteria of the International Classification of Headache Disorders, (ICHD3 beta, 2013) 
by a neurologist expert in headaches.
14
 Participants were excluded if presented: 1, other 
primary and/or secondary headache; 2, medication overuse headache as defined by the 
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ICHD-III; 3, history of neck or head trauma; 4, any systemic degenerative disease; 5, 
diagnosis of fibromyalgia syndrome; 6, received anesthetic blocks or botulinum toxin 
the previous 6 months; 7, received physical treatment in the neck or head the previous 6 
months; or, 8, pregnancy. All participants read and signed a consent form prior to their 
participation. The local Ethics Committee approved the study desing (URJC 23/2014, 
HUFA 14/104, Aalborg N20140063, CESU 5/2015). 
Headache Diary  
          A headache diary for 4 weeks was used to record the headache clinical features 
and to monitor preventive medication intake.
15 
This diary was recorded at baseline and 
at 6-months follow-up.
 
Patients registered the frequency of headaches (days per week), 
the intensity of the headache attacks on an 11-points numerical pain rate scale
16
 (NPRS; 
0: no pain, 10: the maximum pain), and the duration of each attack (hours per day). All 
patients registered in the diary any change in their preventive medication under their 
neurologist supervision and self-perceived effectiveness of prophylactic medication (no 
effect, moderate, or positive) based on a decrease of 30% on headache frequency.
17
 
Sleep Quality  
         The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality over 
the previous month by including 19 self-reported questions and 5 questions answered by 
bed- or room-mates.
18 
The total score ranges from 0 to 21 where higher score indicates 
worse sleep quality. This questionnaire has shown good internal consistency and test-
retest reliability.
19 
Sleep quality was assessed at baseline. 
Anxiety and Depressive Symptoms 
The Hospital Anxiety and Depression Scale (HADS) is a 14-items self-report 
screening scale indicating the presence of anxiety (7 items, HADS-A) and depression (7 
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items, HADS-D).
20
 Each item scores on a Likert scale (0-3) giving a maximum score of 
21 points for each scale.
21
 The HADS has shown good validity and internal consistency 
in patients with headache.
22
 Anxiety and depression were assessed at baseline. 
Burden of Headache 
           The Headache Disability Inventory (HDI) was used to evaluate the self-perceived 
burden. This questionnaire consists of 25-items inquiring about the impact of headache 
on emotional (13 items, HDI-E) and physical (12 items, HDI-P) functioning.
23 
A higher 
score suggests a greater emotional or physical headache burden. The HDI has shown 
good stability in patients with headache.
24 
The HDI was assessed at baseline.  
Trait and State Anxiety Levels 
          The State-Trait Anxiety Inventory (STAI) is a 40-items self-report scale assessing 
state (items l-20, STAI-S) and trait (items 21-40, STAI-T) level of anxiety.
25 
The STAI-
S assesses relatively enduring symptoms of anxiety, and the STAI-T measures a stable 
propensity to experience anxiety, and tendencies to perceive stressful situations as 
threatening. Both subscales showed good internal consistency.
26 
Higher scores indicate 
greater state or trait anxiety levels. Both scales were assessed at baseline. 
Sensitivity to Pressure Pain 
          An electronic pressure algometer (Somedic
®
, Sollentuna, Sweden) was used to 
bilaterally assess pressure pain thresholds (PPT, the minimal amount of pressure where 
a sense of pressure changes to pain) over the temporalis, the cervical spine, the second 
metacarpal, and the tibialis anterior. Pressure was increased at a rate of approximately 
30 kPa/s applied via a 1 cm
2
 rubber coated circular tip. The mean of 3 trials on each 
point, with a 30sec resting period for avoiding temporal summation of pain,
27 
was 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of the article is prohibited.
calculated and used for the analyses. The order of point’s assessment was randomized 
between participants. The reliability of pressure algometry has been found to be high.
28
 
Statistical Analysis  
Means and confidence intervals were calculated. The Kolmogorov-Smirnov test 
revealed that all data had a normal distribution (P>.05). Patients were grouped by use or 
not use of prophylactic medication and by the self-reported effectiveness of medication 
(no effect, moderate, positive effect). Differences between grouped patients in clinical 
features, burden of headache (HDI-E, HDI-P), depression (HADS-D), anxiety (HADS-
A, STAI-T, STAI-S) and sleep quality (PSQI) were compared using one-way analysis 
of variance (ANOVA). Also, a two-way ANOVA was used to evaluate the differences 
in PPT with side as within-subjects factor and group as the between-subjects factor. The 
normality and homogeneity criteria were checked for the dependent variables with 
Kurtosis and Skewness for the normality and Levene’s test for the homogeneity criteria. 
Separate ANOVAs were performed for each variable. As multiple comparisons were 
conducted in the main analysis, a Bonferroni-corrected alpha level of .025 (2 in-
dependent-samples t tests) was required to accept the statistically significance.  
Results 
Clinical Data of the sample 
 A total of 220 individuals with headache were screened for possible eligibility 
criteria. Finally, 180 patients with TTH (72% women) satisfied all eligibility criteria, 
agreed to participate and signed the informed consent at baseline. Forty patients were 
excluded: co-morbid migraine (n=20), previous whiplash injury (n=8), medication 
overuse headache (n=8), or fibromyalgia (n=4). One hundred and seventy-three (n=173, 
96%) were assessed at 6-months follow-up and therefore included in the main analysis. 
Demographic data and outcome measure scores are listed in Table 1. 
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Taking or not taking prophylactic medication 
 Forty-nine (28%) reported taking prophylactic medication for their headaches 
(amitriptyline: 100%). Significant difference in the distribution of patients with FETTH 
and CTTH (P=0.006), years with headache (P=0.01), headache frequency (P=0.003), 
physical (HDI-P, P=0.024) and emotional (HDI-E, P=0.001) burden of headache, sleep 
quality (PSQI, P=0.023) and depression (HADS-D, P=0.001) were observed between 
individuals taking or not taking prophylactic medication. The post hoc analysis revealed 
a higher proportion of patients with CTTH, those with longer headache history, higher 
frequency of headaches, higher physical and emotional headache burden, worse quality 
of sleep and higher depressive levels within the prophylactic medication group (Table 
1). No significant differences in gender (P=0.929), age (P=0.217), intensity of headache 
(P=0.144), headache duration (P=0.172), HADS-A (P=0.734), STAI-T (P=0.553), and 
STAI-S (P=0.482) were found between those patients taking or not taking prophylactic 
medication (Table 1). Similarly, no significant differences in widespread pressure pain 
sensitivity were either found (temporalis: F=0.374, P=0.542; cervical spine: F=0.133, 
P=0.716; second metacarpal: F=0.747, P=0.389; or tibialis anterior muscle: F=0.021, 
P=0.884) (Table 2).  
Self-reported effectiveness of prophylactic medication 
 From those taking prophylactic medication, 11 (23%) reported no effect, other 
25 (51%) reported moderate effect, and the remaining 13 (26%) experienced positive 
effect with the medication. No significant differences in the distribution of patients with 
FETTH and CTTH (P=0.740), gender (P=0.260), age (P=0.843), years with headache 
(P=0.199), headache intensity (P=0.785), headache frequency (P=0.822), headache 
duration (P=0.264), HADS-D (P=0.364), HADS-A (P=0.631), HDI-P (P=0.909), HDI-E 
(P=0.786), STAI-T (P=0.692), STAI-S (P=0.845), PSQI (P=0.619), and PPTs over C5-
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C6 joint (F=0.213, P=0.809), temporalis muscle (F=1.401, P=0.257), or second 
metacarpal (F=0.816, P=0.449) were observed depending on the self-reported effects of 
preventive medication (Tables 3-4). Further, significant differences in PPTs over the 
tibialis anterior muscle (F=4.103, P=0.022) were found: patients reporting no effect of 
prophylactic medication exhibited lower PPTs over the tibialis anterior muscle than 
those reporting moderate or positive effect of the medication (Table 4). 
Discussion 
        This longitudinal study investigating the variables associated with the consumption 
of prophylactic medication intake in individuals with FETTH/CTTH observed that the 
use of prophylactic medication was associated with a higher frequency of headaches, 
higher headache burden, worse sleep quality and higher depressive symptoms, but not 
to other clinical, psychological or pain sensitivity outcomes. Further, no differences in 
clinical, psychological and sensitivity outcomes, only for PPTs in the tibialis anterior, 
were reported based on the self-reported effectiveness of prophylactic medication.  
Prophylactic medication consumption in TTH 
           In our study, 28% of our sample of patients with TTH reported taking regularly 
prophylactic medication, similar to a study conducted in Austria where 38% of their 
patients with headache, mostly TTH and migraine, also used prophylactic medication.
29 
In fact, amitriptyline was the prophylactic medication mostly used by patients with TTH 
in our study and Zebenholzer et al study.
29
 A significant higher proportion (61%) of 
individuals with CTTH tends to use prophylactic medication as compared to those with 
FETTH (39%). Our data agree with a previous study reporting that chronic headache 
sufferers are more likely to use medication than episodic headache sufferers.
30 
It seems 
that medication consumption patterns may be different between patients with chronic or 
episodic (with low frequency of attacks) headaches. It is interesting to note that 70% of 
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our sample of patients with TTH did not take prophylactic treatment at the moment of 
the study. We do not know the reasons for that situation. For instance, it is possible that 
some patients have never taken prophylactic medication for TTH. It is also possible that 
others had stopped the medication intake due to absence of effectiveness or because the 
presence of adverse events. In fact, most of these patients (65%) reported a sporadic use 
of symptomatic medication intake (100% NSAIDs) when the headache attack is intense.   
Patients consuming prophylactic medication exhibited higher headache burden, 
worse sleep quality and higher depressive symptoms, but not to clinical, pain sensitivity 
or psychological outcomes, than those not consuming medication. These findings may 
be related to the fact that higher headache burden, worse sleep quality and depression 
are outcomes associated with a higher frequency of the headaches;
31,32 
therefore, since a 
higher proportion of patients with CTTH taken prophylactic amitriptyline medication, 
these features maybe more related to this situation rather than to the medication intake 
pattern. Since higher frequency of headache attcaks
33 
and emotional burden
34 
can lead 
to excitability of central nervous system, it appears that prophylactic medication would 
be consumed by individuals with central sensitization. Further, the comorbid association 
between higher frequency of headache attacks and depression in these patients would 
explain that the prophylactic medication most used was a tricyclic antidepressant such 
as amitriptyline. Nevertheless, although antidepressants are often prescribed to patients 
with headache under the assumption that they will be also effective for reducing the 
comorbid depression, the majority of studies have failed to find a relationship between 
depression symptoms and headache clinical improvement.
35 
It seems that prophylactic 
medication would lead to a reduction of headache due to anti-nociceptive effects rather 
than to an antidepressant effect which may be related to the fact that dose recommended 
for headache is lower than dose used for the management of depression. 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of the article is prohibited.
Self-perceived effectiveness of prophylactic medication intake 
In our study, 27% of our sample taking prophylactic amitriptyline medication 
reported a positive effect by a reduction on frequency of headache. No differences were 
observed based on the effectiveness of prophylactic medication, except for the fact that 
patients reporting no effect of prophylactic medication exhibited lower PPTs over the 
tibialis anterior muscle than those reporting moderate or positive effect with medication. 
These results suggest that prophylactic medication would be less effective in individuals 
with widespread pressure pain hypersensitivity, a manifestation of central sensitization.
7
 
This hypothesis would be supported by a study showing that amitriptyline was effective 
for reducing peri-cranial muscle tenderness in those patients who clinically responded to 
medication (30% reduction in headache).
36 
Additionally, it should be noted that patients 
taking prophylactic medication also took symptomatic medication sporadically, mostly 
when an attack was intense. Interestingly, no differences in the symptomatic medication 
based on the effectiveness of prophylactic medication was observed. Nevertheless, due 
to the small sample of patients in this group, population-based studies are now needed. 
A recent meta-analysis reported that depression, poor sleep and emotional stress 
(burden) were associated with unfavorable outcomes from prophylactic treatment,
13
 
which disagree with current results. It is probably that the reduced number of patients 
within the no effect group would lead to lower statistical power.  
Strength and limitations 
Although strengths of the current study include a large sample size, the inclusion 
of patients accordingly to the most updated diagnostic criteria, the use of diagnostic 
diaries and a longitudinal study design, some limitations should be also recognized. 
First, we included volunteer patients from headache centers; therefore, they may be not 
representative of the general population. Second, data for depression and sleep quality 
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were smaller than expected, which could be related to the questionnaires employed in 
the study. For instance, the HADS is considered a screening rather than a diagnostic 
instrument for depressive symptoms with a tendency to underestimate its prevalence.
37 
We do not know if the use of other outcomes could lead to different results. Third, the 
effectiveness of prophylactic medication was self-reported by the patients; so, this could 
have been biased. In fact, we do not know if a lack of effectiveness is a potential reason 
why most of our sample (70%) did not report prophylactic medication intake at the time 
of the study. Finally, we do not know if the associations identified in the current study 
will be maintained with longer follow-up periods since it seems that medication intake 
patterns change during time in patients with TTH. 
Conclusions 
         This 6 months longitudinal study found that the use of prophylactic amitriptyline 
medication was associated with a higher frequency of headaches, higher headache 
burden, worse sleep quality, and higher depressive symptoms, but not to other clinical, 
psychological or pain sensitivity outcomes in TTH. Lower effectiveness of prophylactic 
medication was associated with widespread pressure pain hyperalgesia. 
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Table 1: Clinical features, psychological and related-disability 
outcomes in patients with tension-type headache in the total sample 
and with and without prophylactic medication intake (n=173) 
 Total sample 
(n=173) 
Taking 
medication 
(n=49) 
No taking 
medication 
(n=124) 
Clinical Pain Features 
Gender (male/female) 
n (%) 
49 (28%) / 
124 (72%) 
14 (29%) / 35 
(71%) 
35 (28%) / 89 
(72%) 
FETTH / CTTH n 
(%)* 
98 (57%) / 75 
(43%) 
19 (39%) / 30 
(61%) 
79 (64%) / 45 
(36%) 
Age (years) 48 (45, 51) 47 (43, 51) 48 (46, 50) 
Headache history 
(years)* 
10.6 (8.7, 
12.5) 
14.5 (11.4, 17.6) 9.3 (7.3, 11.3) 
Headache intensity (0-
10) 
6.1 (5.7, 6.5) 6.3 (6.0, 6.6) 6.0 (5.5, 6.5) 
Headache frequency 
(days/month)* 
16.7 (13.3, 
20.1) 
19.2 (14.7, 23.7) 15.4 (13.8, 17.0) 
Headache duration 
(hours per attack) 
7.2 (6.5, 7.9) 8.0 (6.5, 9.5) 7.0 (6.2, 7.8) 
Psychological and disability-related outcomes 
HADS-D (0-21)* 8.3 (7.5, 9.1) 9.7 (8.1,11.3) 7.1 (6.3, 7.9) 
HADS-A (0-21) 10.0 (9.2, 
10.8) 
10.1 (8.9, 12.3) 9.8 (8.8, 10.8) 
HDI-P (0-48)* 23.2 (21.2, 
25.2) 
 26.2 (23.5, 29.0) 21.3 (19.4, 23.2) 
HDI-E (0-52)* 19.7 (17.5, 
21.9) 
24.1 (19.6, 28.6) 16.7 (14.6, 18.8) 
STAI-T (0-60) 23.9 (22.7, 
25.1) 
23.4 (21.7, 25.1) 24.1 (22.5, 25.7) 
STAI-S (0-60) 21.7 (20.7, 
22.7) 
21.3 (19.7, 22.9) 22.0 (20.6, 23.4) 
PSQI (0-21)* 8.3 (7.5, 9.1) 9.3 (7.7, 10.9) 7.7 (7.0, 8.6) 
Values are expressed as means (95% confidence interval); * Significant 
differences between groups (ANOVA, P<0.025) 
FETTH: Frequent episodic tension type headache; CTTH: Chronic tension 
type headache; HADS: Hospital Anxiety and Depression Scale (D: 
Depression; A: Anxiety), HDI: Headache Disability Inventory (P: Physical; 
E: Emotional), STAI: State-Trait Anxiety Inventory (T: Trait; S: State); 
PSQI: Pittsburgh Sleep Quality Index 
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Table 2: Differences in pressure pain thresholds (PPT, kPa) 
between individuals with tension-type headache with and without 
prophylactic medication intake (n=173) 
 Temporalis 
muscle 
Cervical Spine Second 
metacarpal 
Tibialis 
anterior 
muscle 
Taking medication (n=49) 
Right 
side 
202.5 (181.5, 
223.5) 
189.9 (157.8, 
222.0) 
264.5 (238.0, 
291.0) 
411.6 (371.3, 
451.9) 
Left 
side 
196.6 (174.3, 
218.9) 
199.3 (168.7, 
229.9) 
261.6 (236.3, 
286.9) 
407.8 (366.2, 
449.4) 
No taking medication (n=124) 
Right 
side 
216.2 (198.6, 
233.8) 
212.1 (192.1, 
232.1) 
248.5 (229.5, 
267.5) 
406.2 (368.6, 
443.8) 
Left 
side 
196.0 (180.8, 
211.2) 
213.0 (193.9, 
232.1) 
250.8 (232.1, 
269.5) 
400.6 (363.0, 
438.2) 
Values are expressed as means (95% confidence interval)  
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Table 3: Clinical features, psychological and related-disability 
outcomes in patients with tension-type headache depending on the 
self-reported perception of effectiveness of prophylactic 
medication (n=49) 
 No Effect 
(n=11) 
Moderate Effect 
(n=25) 
Positive 
Effect (n=13) 
Clinical Pain Features 
Gender (male/female) n 
(%) 
3 (27%) / 9 
(73%) 
7 (28%) / 18 
(72%) 
4 (31%) / 9 
(69%) 
FETTH / CTTH n (%) 4 (36%) / 7 
(64%) 
10 (40%) / 15 
(60%) 
5 (38%) / 8 
(62%) 
Age (years) 47 (44, 50) 48 (45, 51) 46 (44, 48) 
Headache history (years) 12.5 (10.0, 15.0) 16.9 (13.9, 19.9) 16.3 (12.6, 
20.0) 
Headache intensity (0-10) 6.0 (5.1, 6.9) 6.5 (5.9, 7.1) 6.7 (6.0, 7.4) 
Headache frequency 
(days/) 
18.2 (13.5, 22.9) 20.9 (17.5, 24.3) 19.4 (18.2, 
20.6) 
Headache duration (hours 
per attack) 
8.2 (6.8, 9.6) 8.1 (7.0, 9.2) 7.8 (6.3, 9.3) 
Psychological and disability-related outcomes 
HADS-D (0-21) 11.2 (9.5, 12.9) 9.4 (8.2, 10.6) 9.6 (8.0, 11.2) 
HADS-A (0-21) 11.1 (8.5, 12.7) 10.0 (8.2, 11.8) 9.3 (8.3, 10.3) 
HDI-P (0-48)  26.9 (24.7, 
29.2) 
25.9 (23.8, 28.0) 25.7 (24.0, 
27.4) 
HDI-E (0-52) 23.8 (19.3, 28.3) 24.4 (20.7, 28.1) 23.9 (20.9, 
26.9) 
STAI-T (0-60) 23.3 (21.6, 25.0) 23.9 (22.1, 24.7) 22.8 (20.0, 
25.6) 
STAI-S (0-60) 20.5 (18.4, 22.6) 21.3 (19.1, 23.5) 21.7 (20.3, 
23.1) 
PSQI (0-21) 9.7 (8.4, 11.0) 8.8 (7.6, 10.0) 9.6 (8.5, 10.7) 
Values are expressed as means (95% confidence interval)  
FETTH: Frequent episodic tension type headache; CTTH: Chronic tension 
type headache; HADS: Hospital Anxiety and Depression Scale (D: 
Depression; A: Anxiety), HDI: Headache Disability Inventory (P: Physical; 
E: Emotional), STAI: State-Trait Anxiety Inventory (T: Trait; S: State); 
PSQI: Pittsburgh Sleep Quality Index 
  
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of the article is prohibited.
 
 
Table 4: Differences in pressure pain thresholds (PPT, kPa) in 
individuals with tension-type headache depending on the self-
reported perception of effectiveness of prophylactic medication 
(n=49) 
 Temporalis 
muscle 
Cervical Spine Second 
metacarpal  
Tibialis 
anterior 
muscle* 
No Effect (n=11) 
Right 
side 
186.7 (167.3, 
206.1) 
189.8 (157.3, 
222.4) 
260.8 (232.1, 
289.5) 
357.2 (322.3, 
392.1) 
Left 
side 
196.3 (168.1, 
224.5) 
195.0 (682.1, 
227.9) 
260.5 (237.2, 
283.2) 
354.0 (321.9, 
386.1) 
Moderate Effect (n=25) 
Right 
side 
208.9 (185.9, 
231.9) 
193.2 (159.4, 
227.0) 
261.2 (236.6, 
285.8) 
417.3 (367.7, 
466.9) 
Left 
side 
196.5 (172.5, 
220.5) 
207.3 (183.6, 
231.0) 
265.9 (238.1, 
293.7) 
422.9 (366.7, 
479.1) 
Positive Effect (n=13) 
Right 
side 
198.7 (170.5, 
226.9) 
183.0 (153.7, 
212.3) 
272.1 (247.5, 
296.7) 
432.5 (390.4, 
474.6) 
Left 
side 
195.2 (169.4, 
221.0) 
197.1 (161.5, 
232.7) 
258.4 (232.2, 
284.6) 
434.1 (392.9, 
475.3) 
Values are expressed as means (95% confidence interval); * Significant 
differences between groups (ANOVA, P<0.025) 
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